Re-engineered plant compound treats opioid addiction in mice

February 05, 2020

The abuse of prescription and illegal opioids, such as morphine and heroin, is a major problem in the U.S., with devastating public health, economic and social consequences. That's why scientists are searching for new medicines to help break the cycle of addiction. Now, researchers reporting in ACS' Journal of Medicinal Chemistry have re-engineered the structure of vincamine, a plant-derived compound, so that it reduces morphine-seeking behaviors in mice. 

According to the U.S. Centers for Disease Control and Prevention, more than 130 people died each day from an opioid overdose in 2017. To develop a drug to treat opioid addiction, Robert Huigens III, and colleagues wondered if they could use a natural product as a starting point to synthesize new compounds. Many plant-produced compounds have complex structures that can bind to therapeutically relevant biological targets. Huigens reasoned that by altering the structure of one such compound, vincamine -- an indole alkaloid from the leaves of the plant Vinca minor -- they might obtain a molecule that binds to new protein targets involved in opioid addiction, thereby blocking the drugs' "high" sensations. 

The team altered vincamine's chemical structure, producing a diverse library of 80 small molecules. They then screened seven of these molecules for the ability to bind to certain protein receptors and block their action. One of the molecules, which they refer to as "V2a," inhibited a protein called hypocretin receptor 2 (HCRTR2) that is involved in heroin dependence, whereas the parent compound, vincamine, had no effect. The researchers then tested this compound in mice, finding that pretreatment with V2a prevented mice from spending extra time in a chamber where morphine is administered. In another experiment, mice that had "recovered" from morphine addiction, and then were treated with V2a, did not relapse to morphine-seeking behaviors in response to stress, unlike mice that were not treated with the new molecule. The team also conducted molecular modeling experiments to visualize how the compound binds to HCRTR2, which could allow them to tweak the structure of the compound for even stronger binding and efficacy.
The authors acknowledge funding from the University of Florida, the American Cancer Society, the National Institutes of Health, the Debbie and Sylvia DeSantis Chair in Natural Products Drug Discovery and Development and the National Science Foundation.

The abstract that accompanies this study is available here.

For more research news, journalists and public information officers are encouraged to apply for complimentary press registration for the ACS Spring 2020 National Meeting & Exposition in Philadelphia.

The American Chemical Society (ACS) is a nonprofit organization chartered by the U.S. Congress. ACS' mission is to advance the broader chemistry enterprise and its practitioners for the benefit of Earth and its people. The Society is a global leader in providing access to chemistry-related information and research through its multiple research solutions, peer-reviewed journals, scientific conferences, eBooks and weekly news periodical Chemical & Engineering News. ACS journals are among the most cited, most trusted and most read within the scientific literature; however, ACS itself does not conduct chemical research. As a specialist in scientific information solutions (including SciFinder® and STN®), its CAS division powers global research, discovery and innovation. ACS' main offices are in Washington, D.C., and Columbus, Ohio.

To automatically receive news releases from the American Chemical Society, contact

Follow us on Twitter | Facebook

American Chemical Society

Related Addiction Articles from Brightsurf:

Opioid addiction treatment is more widely available, but only for adults
Primary care providers have expanded access to buprenorphine for adults, but use of the opioid addiction treatment has decreased among the youngest patients, find researchers at Columbia University.

Is video game addiction real?
A recent six-year study, the longest study ever done on video game addiction, found that about 90% of gamers do not play in a way that is harmful or causes negative long-term consequences.

Eating disorders linked to exercise addiction
New research shows that exercise addiction is nearly four times more common amongst people with an eating disorder.

Co-addiction of meth and opioids hinders treatment
A study published in the Journal of Substance Abuse Treatment found that methamphetamine use was associated with more than twice the risk for dropping out of treatment for opioid-use disorder.

New tool to assess digital addiction in children
A new study developed and validated a tool for assessing children's overall addiction to digital devices.

Addiction intervention in hospital is a 'reachable moment'
Patients who meet an addiction medicine consult team while they're in the hospital are twice as likely to participate in treatment for substance use disorder after they go home, according to new research.

How stress leads to Facebook addiction
Friends on social media such as Facebook can be a great source of comfort during periods of stress.

Systematic review of food addiction as measured with the Yale Food Addiction Scale
The aim of this paper was to review the clinical significance of food addiction diagnoses made with the Yale Food Addiction Scale (YFAS) and to discuss the results in light of the current debate on behavioral addictions.

Drugs of abuse: Identifying the addiction circuit
What happens in the brain of a compulsive drug user?

Pancreatic cancer's addiction could be its end
Researchers at CSHL have discovered that an inappropriately produced protein may be why some pancreatic cancer patients die exceptionally early.

Read More: Addiction News and Addiction Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to